Key result
In adults with a 22q11.2 microdeletion, the triglyceride polygenic risk score was a significant predictor of triglyceride levels (beta = 0.313, p=1.52E-04), explaining 8.4% of the variance in a multivariable model.
Why the study?
The 22q11.2 microdeletion confers a 2-fold increased risk for mild-moderate hypertriglyceridemia, but the role of a triglyceride polygenic risk score in individuals with this elevated baseline risk was unknown.
Does a triglyceride polygenic risk score predict mild-moderate hypertriglyceridemia in adults with a 22q11.2 microdeletion?
Cohort (n=157)
Does a triglyceride polygenic risk score predict mild-moderate hypertriglyceridemia in adults with a 22q11.2 microdeletion?
A polygenic risk score for triglycerides, along with sex and BMI, helps predict mild-moderate hypertriglyceridemia in adults with a 22q11.2 microdeletion.
TG-PRS independently predicts TG levels in 22q11.2 deletion carriers; supports additive polygenic effects on variable expression but remains hypothesis-generating for clinical use.
BACKGROUND: Elevated triglyceride (TG) levels are a heritable and modifiable risk factor for cardiovascular disease and have well-established associations with common genetic variation captured in a polygenic risk score (PRS). In young adulthood, the 22q11.2 microdeletion conveys a 2-fold increased risk for mild-moderate hypertriglyceridemia. This study aimed to assess the role of the TG-PRS in individuals with this elevated baseline risk for mild-moderate hypertriglyceridemia. METHODS: We studied a deeply phenotyped cohort of adults (n = 157, median age 34 years) with a 22q11.2 microdeletion and available genome sequencing, lipid level, and other clinical data. The association between a previously developed TG-PRS and TG levels was assessed using a multivariable regression model adjusting for effects of sex, BMI, and other covariates. We also constructed receiver operating characteristic (ROC) curves using logistic regression models to assess the ability of TG-PRS and significant clinical variables to predict mild-moderate hypertriglyceridemia status. The effect of TG-PRS appeared to be slightly stronger in individuals with obesity (BMI ≥ 30) (beta = 0.4617) than without (beta = 0.1778), in a model unadjusted for other covariates (p-interaction = 0.045). Among ROC curves constructed, the inclusion of TG-PRS, sex, and BMI as predictor variables produced the greatest area under the curve (0.749) for classifying those with mild-moderate hypertriglyceridemia, achieving an optimal sensitivity and specificity of 0.746 and 0.707, respectively. CONCLUSIONS: These results demonstrate that in addition to significant effects of sex and BMI, genome-wide common variation captured in a PRS also contributes to the variable expression of the 22q11.2 microdeletion with respect to elevated TG levels.
No takes yet. Share an insight, caveat, or question.
Ying et al. (2023) conducted a cohort in 22q11.2 deletion syndrome (n=157). Triglyceride polygenic risk score (TG-PRS) was evaluated on Triglyceride (TG) levels (beta = 0.313, p=1.52E-04). In adults with a 22q11.2 microdeletion, the triglyceride polygenic risk score was a significant predictor of triglyceride levels (beta = 0.313, p=1.52E-04), explaining 8.4% of the variance in a multivariable model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: